Sanctuary Advisors’s Akebia Therapeutics AKBA Stock Holding History

Sanctuary Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,278	Closed	-$36.2K	–	2418
2025 Q3	$36.2K	Buy	+13,278	New	+$44.2K	﹤0.01%	2394

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sanctuary Advisors's AKBA Position: Q4 2025 in Review

Sanctuary Advisors sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 13,278 shares — an estimated $36.2K sold.

Sanctuary Advisors first reported a position in AKBA in Q3 2025 and held it in 1 quarter. The position peaked at $36.2K in Q3 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

Sanctuary Advisors reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
Sanctuary Advisors sold 13,278 Akebia Therapeutics shares in Q4 2025, an estimated $36.2K.
Sanctuary Advisors first reported a position in Akebia Therapeutics in Q3 2025 and held it in 1 quarter.
Sanctuary Advisors's Akebia Therapeutics position peaked at $36.2K in Q3 2025.
165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Sanctuary Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.